Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?

Lisa M. Lima, Keeran Sampat, Sarit Assouline, Debra Saxe, Sharron Nault, Mourad Tighiouart, Morgan McLemor, Martha Arellano, Elliott Winton, Leon Bernal-Mizrachi, Jorge Cortes, Hanna Jean Khoury

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Imatinib (IM)-associated myelosuppression is rare in gastrointestinal stromal cell tumors (<10%) but common in chronic myeloid leukemia (CML). Selective inhibition of predominantly Philadelphia chromosome (Ph+) driven hematopoiesis may explain myelosuppression in CML. In the absence of clinical methods to quantitate the Ph+/Ph- progenitor ratio, we hypothesized that the pre-IM percentage of BCR-ABL+ cells measured by fluorescence in situ hybridization (FISH) predicts for myelosuppression. FISH analyses performed within 30 days pre-IM 400 mg/day were analyzed in 89 patients with chronic phase CML at three institutions. Patients who developed grade ≥3 cytopenias had a higher percentage of positive FISH (90% vs. 83%; p = 0.02). Cytopenias lasted a median of 16 days, and all patients but one continued IM, achieved complete hematologic and cytogenetic remissions, and did not experience progression, with a follow-up of 61 months. In conclusion, IM-associated cytopenias are associated with a high pre-IM FISH, are reversible, and do not adversely affect outcomes.

Original languageEnglish (US)
Pages (from-to)1010-1016
Number of pages7
JournalLeukemia and Lymphoma
Volume52
Issue number6
DOIs
Publication statusPublished - Jun 1 2011
Externally publishedYes

    Fingerprint

Keywords

  • CML
  • imatinib
  • Myelosuppression
  • outcomes
  • risk

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this